Every other Thursday, HEMEX showcases smart ideas and solutions from innovation-driven start-ups that aim to improve our future healthcare services. This morning, we had the pleasure of hosting a very special HEMEX Investment Showcase, where project lead, Dr. Myriam Lingg, brilliantly presented macu4’s innovative idea to revolutionize the passive-arm prosthetics market.
Collaboration Funding Innovation Press Release Regulatory
Revolutionising biomedical data sharing and AI-driven healthcare solutions
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue readingInnovation, Press Release
InQbator: New startup incubator & accelerator powered by BLKB, HEMEX & Launchpad
BLKB, HEMEX and Launchpad aim to support young entrepreneurs in their business activities through the start-up incubator program, inQbator. The program is open to start-ups from all industries. The main aim of inQbator is to promote innovation in the region.
February is undeniably the month of love, kindness, and compassion. However, sometimes the society in which we live can be seen as this hostile, unfriendly, and a cruel place. Especially in the last year, we have lived through an unprecedented situation, and all of us had to adapt to a new normality. Scientific evidence shows the positive effects of doing random acts of kindness for others as well as receiving them, so why don’t we get started?
Our portfolio company Opterion Health AG seeks to enhance the quality of life for patients with end-stage renal disease (ESRD) and their loved ones, and to increase survival rates of ESRD patients. They launched their new website at the beginning of the year and have very exciting plans for 2021!
On HEMEX’s Investment Showcase today we tackled the pain, bleeding, and tissue tear that women worldwide experience when undergoing common gynaecological procedures. Our portfolio company ASPIVIX is developing the next-generation suction-based cervical device that will improve these traumatic experiences.
We are thrilled to announce the successful completion of an oversubscribed Series C to further accelerate our company’s growth.
HEMEX is delighted to announce our exciting new partnership with SMART-TRIAL. Collecting and managing clinical data has been revolutionized for the MedTech industry and we are pleased that eCRF, eConsent, and more can now be done with confidence. This partnership enables us to provide healthcare start-ups with a complete range of packages to ensure conducting clinical trials, PMCF studies, and monitoring is made easy and affordable.
HEMEX’s Investment Showcase featured today TOM Medications. The digital health company has developed the app that will make easier the lives of millions of patients with chronic diseases at an early stage.
The final 3 steps that will enable you to conclude your clinical development process. Find out how can you thoroughly REPORT your study results with HEMEX Contract Research Organization!
Galventa was the start-up selected to launch this series of events, which will take place throughout the first three months of 2021